Solvay Patent-Cliff Exposure & CMS Drug Spending Portfolio
Solvay (US): 1 reconciled FDA prescription therapies, $73.6M 2024 CMS Part D & Medicaid spend, and 17 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $73.6M |
| 2024 Medicare Part D Spend | $60.5M |
| 2024 Medicaid Spend | $13.2M |
| California HCAI SB 17 Filings | 17 WAC filings (max 167.3% 2-yr change) |